Adc Therapeutics Sa (ADCT) Stock Price, Quote & News

Company Profile

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 21 653 02 00

Website: www.adctherapeutics.com

Address:

BiopOle, Route de la Corniche 3B, Epalinges, Switzerland

SamHot Dec. 23 at 9:59 PM

$ADCT I couldn't resist

0 · Reply

Justrise07 Dec. 11 at 6:08 PM

$ADCT silent monster ! Shorts already started recovering! They read the new update & did dd , unstoppable next stop , welcome $CAPR

0 · Reply

josegodoy Dec. 11 at 12:44 AM

$ADCT

0 · Reply

jdkd4 Dec. 10 at 10:22 PM

$ADCT thx Jacksparo for another wonderful alert. Made a nice small profit. I set my own plan for this one and I’m executing it today. Follow the rules that I set! sure I could lose out on more profit, but profit is profit is profit. I have learned that over and over again from my mentor, Jacksparo!!!!!!!

2 · Reply

Andysss Dec. 10 at 8:26 PM

$ADCT told u. If u sold due to the data. Stop investing in biotech

1 · Reply

DARKP00L Dec. 10 at 7:59 PM

$ADCT this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

Andysss Dec. 10 at 3:02 PM

$ADCT some exited their short position. Will fly

0 · Reply

RadioIsotope25 Dec. 10 at 1:06 PM

$VNDA $ADCT $CAPR $PBYI

0 · Reply

Andysss Dec. 9 at 8:14 PM

$ADCT Market stating to understand the data.

0 · Reply

SuperGreenToday Dec. 9 at 4:44 PM

$ADCT Share Price: $3.27 Contract Selected: Jul 17, 2026 $5 Calls Buy Zone: $0.57 – $0.71 Target Zone: $0.92 – $1.12 Potential Upside: 51% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript

$ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma$

Dec 3, 2025, 7:30 AM EST - 22 days ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Dec 2, 2025, 4:05 PM EST - 22 days ago

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

Dec 1, 2025, 4:05 PM EST - 23 days ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Nov 10, 2025, 11:21 AM EST - 6 weeks ago

ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 7:30 AM EST - 6 weeks ago

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 3, 2025, 7:15 AM EST - 7 weeks ago

ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025

Oct 27, 2025, 7:15 AM EDT - 2 months ago

ADC Therapeutics to Present at November Investor Conferences

Oct 13, 2025, 7:30 AM EDT - 2 months ago

ADC Therapeutics Announces $60 Million Private Placement

Aug 27, 2025, 7:15 AM EDT - 4 months ago

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

Aug 12, 2025, 11:27 AM EDT - 4 months ago

ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:30 AM EDT - 4 months ago

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 5, 2025, 4:05 PM EDT - 5 months ago

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

Jul 1, 2025, 4:05 PM EDT - 6 months ago

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

Jun 16, 2025, 7:15 AM EDT - 6 months ago

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

Jun 12, 2025, 6:45 AM EDT - 7 months ago

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

Jun 12, 2025, 6:30 AM EDT - 7 months ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

May 15, 2025, 7:15 AM EDT - 8 months ago

ADC Therapeutics to Present at Upcoming Investor Conferences

May 14, 2025, 12:36 PM EDT - 8 months ago

ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript

May 14, 2025, 8:00 AM EDT - 8 months ago

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

May 14, 2025, 7:45 AM EDT - 8 months ago

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

May 8, 2025, 7:15 AM EDT - 8 months ago

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

Apr 28, 2025, 7:00 AM EDT - 8 months ago

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

Apr 1, 2025, 7:15 AM EDT - 9 months ago

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 11:17 AM EDT - 9 months ago

ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:30 AM EDT - 9 months ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

Mar 25, 2025, 5:30 PM EDT - 9 months ago

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Mar 24, 2025, 11:08 PM EDT - 9 months ago

ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025

Mar 20, 2025, 7:15 AM EDT - 10 months ago

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

Jan 30, 2025, 7:15 AM EST - 11 months ago

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Dec 30, 2024, 4:30 PM EST - 1 year ago

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

Dec 12, 2024, 2:03 PM EST - 1 year ago

ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL

$ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma$

Dec 11, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

$ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma$

Dec 9, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

Dec 6, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

Nov 9, 2024, 11:01 AM EST - 1 year ago

ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 1:14 PM EST - 1 year ago

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

Nov 7, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

Nov 5, 2024, 9:47 AM EST - 1 year ago

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

Oct 31, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Aug 11, 2024, 9:26 AM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:30 AM EDT - 1 year ago

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Jul 30, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

Jul 8, 2024, 2:00 AM EDT - 1 year ago

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

Jun 27, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

May 30, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 15, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 9, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

May 6, 2024, 11:04 AM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript

SamHot Dec. 23 at 9:59 PM

$ADCT I couldn't resist

0 · Reply

Justrise07 Dec. 11 at 6:08 PM

$ADCT silent monster ! Shorts already started recovering! They read the new update & did dd , unstoppable next stop , welcome $CAPR

0 · Reply

josegodoy Dec. 11 at 12:44 AM

$ADCT

0 · Reply

jdkd4 Dec. 10 at 10:22 PM

2 · Reply

Andysss Dec. 10 at 8:26 PM

$ADCT told u. If u sold due to the data. Stop investing in biotech

1 · Reply

DARKP00L Dec. 10 at 7:59 PM

$ADCT this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

Andysss Dec. 10 at 3:02 PM

$ADCT some exited their short position. Will fly

0 · Reply

RadioIsotope25 Dec. 10 at 1:06 PM

$VNDA $ADCT $CAPR $PBYI

0 · Reply

Andysss Dec. 9 at 8:14 PM

$ADCT Market stating to understand the data.

0 · Reply

SuperGreenToday Dec. 9 at 4:44 PM

0 · Reply

Arcides Dec. 9 at 12:26 AM

$ADCT buyers are losing the battle.

0 · Reply

Adamchristlover Dec. 5 at 10:41 PM

$ADCT $CAPR $KALA $AQST $EKSO I support this post and approve it 100% as I am also part of Jack team and I have my brokerage statements for whoever needs it.

0 · Reply

jdkd4 Dec. 5 at 10:26 PM

$ADCT $CAPR $KALA $AQST $EKSO And many more tickers. I have made money, over $40,000 this week simply by following Jacksparo alerts! I have very limited knowledge about investing, but I subscribe to his services and I can tell you for sure he over delivers most of the time! I am a very happy customer!!!! If you look at my post history you’ll see I have posted pictures of most of my trades to verify these. Thank you, Jack! You’re changing my life!

10 · Reply

alikp76 Dec. 5 at 8:43 PM

$ADCT shit happens over and over again 🫥

0 · Reply

fort_worth_Jason Dec. 5 at 3:35 PM

$ADCT - I don't understand why people are selling shares so cheap. There will be a "big update" in 1H2026 on Lotis 5 trial. Redmile is still holding.

2 · Reply

fort_worth_Jason Dec. 5 at 3:09 PM

$ADCT Buying more while it is discounted.

0 · Reply

jacksparo Dec. 4 at 7:32 PM

$GUTS $ADCT $BULL $ESPR I am looking into new trade opportunities Let’s us see what we have in 2026/27 Journey 📈📈✅📈📈✅! I will share my trade ideas via the email / Telegram as usual 📈📈📈!

4 · Reply

Godwinsol Dec. 4 at 5:54 PM

$ADCT lol. Chatgpt will only give you as good a response as the question is. All alternative therapies have same AEs profile and G5 fatality rate. This is best in class. Side effects profile is standard. CRS is easily managed with anti-IL6

2 · Reply

Spartrap Dec. 4 at 3:53 PM

$ADCT

0 · Reply

fort_worth_Jason Dec. 4 at 3:15 PM

$ADCT we need to keep message volume high to keep this on Stockwits' radar. Let's go!!!

0 · Reply

fort_worth_Jason Dec. 4 at 2:06 PM

$ADCT For those concerned over the safety profile and unfortunate patient event, I decided to do more research on the half-life and elimination of the drug. Zynlonta's half-life is roughly 3 weeks. The patient event occured more than 105 days or 11 weeks after their last dose. Based on drug elimination, there would have been less than 12% of the drug in patient's system. My opinion (not doctor) is that the investigor's connection to Zynlonta is weak because very little of the drug remains. I would expect the event to occur when drug concentrations are higher, not lower. I remain bullish on this company and drug.

1 · Reply

Andysss Dec. 4 at 1:37 PM

$ADCT entered yesterday. clear overreaction. deliverers best-in-class efficacy and the safety profile showed no new signals. Toxicity remains comparable to or better than other 3L+ DLBCL options

1 · Reply

Market Cap	433.57M
Revenue (ttm)	70.84M
Net Income (ttm)	-157.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-222.83%
Debt to Equity Ratio	-0.48

Volume	392,400
Avg Vol	1,260,944
Day's Range	N/A - N/A
Shares Out	123.88M
Stochastic %K	19%
Beta	1.89
Analysts	Strong Sell
Price Target	$8.00